3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Colorectal Neoplasms
3
Skin Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Urologic Neoplasms
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Turcot syndrome
1
Solid Tumors
1
Solid Tumor, Adult
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Motor Activity
1
Lung Neoplasms
1
Locally Advanced Esophageal Squamous Cell Carcinoma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
5
Nivolumab
3
durvalumab
2
atezolizumab
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
denileukin diftitox
1
danvatirsen
1
avelumab
1
Specimen Handling
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Disulfides
1
Diffusion Tensor Imaging
1
Cyclophosphamide
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Turcot syndrome
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled